(Q51367101)

English

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

scientific article published on 7 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21977965

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. (English)

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21977965

type 2 diabetes

0 references

0 references

object named as

I Rychlik

2

0 references

author name string

M Nowicki

1

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21977965

H Haller

3

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21977965

M Warren

4

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21977965

L Suchower

5

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21977965

I Gause-Nilsson

6

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21977965

K-M Schützer

7

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21977965

publication date

7 October 2011

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21977965

International Journal of Clinical Practice

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21977965

65

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21977965

12

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21977965

1230-1239

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21977965

Diabetic nephropathy: important pathophysiologic mechanisms

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Importance of glycemic control on the course of glomerular filtration rate in type 2 diabetes with hypertension and microalbuminuria under tight blood pressure control

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Diagnostic application of the A(1c) assay in renal disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Inter-day glycemic variability assessed by continuous glucose monitoring in insulin-treated type 2 diabetes patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Liraglutide: effects beyond glycaemic control in diabetes treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Analysis of hemodialysis-associated hypoglycemia in patients with type 2 diabetes using a continuous glucose monitoring system

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02812.X

21 January 2018

Identifiers

10.1111/J.1742-1241.2011.02812.X

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21977965

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21977965

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51367101&oldid=1233626824"